These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 37392012)
41. Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review. Nayak SM; Bradley MK; Kleykamp BA; Strain EC; Dworkin RH; Johnson MW J Clin Psychiatry; 2023 May; 84(3):. PubMed ID: 37167563 [No Abstract] [Full Text] [Related]
42. Psychedelics: Where we are now, why we got here, what we must do. Belouin SJ; Henningfield JE Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779 [TBL] [Abstract][Full Text] [Related]
44. The challenges ahead for psychedelic 'medicine'. Muthukumaraswamy S; Forsyth A; Sumner RL Aust N Z J Psychiatry; 2022 Nov; 56(11):1378-1383. PubMed ID: 35243919 [TBL] [Abstract][Full Text] [Related]
45. Probing the Future of Psychedelics for Mental Health. Allen S IEEE Pulse; 2021; 12(4):6-10. PubMed ID: 34375272 [TBL] [Abstract][Full Text] [Related]
46. The Potential of Psychedelics for the Treatment of Episodic Migraine. Schindler EAD Curr Pain Headache Rep; 2023 Sep; 27(9):489-495. PubMed ID: 37540398 [TBL] [Abstract][Full Text] [Related]
47. The Therapeutic Potential of Psilocybin. Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L Molecules; 2021 May; 26(10):. PubMed ID: 34063505 [TBL] [Abstract][Full Text] [Related]
48. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Majić T; Schmidt TT; Gallinat J J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401 [TBL] [Abstract][Full Text] [Related]
49. Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature. Golden TL; Magsamen S; Sandu CC; Lin S; Roebuck GM; Shi KM; Barrett FS Curr Top Behav Neurosci; 2022; 56():35-70. PubMed ID: 35138585 [TBL] [Abstract][Full Text] [Related]
50. LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder. Daldegan-Bueno D; Donegan CJ; Forsyth A; Sumner RL; Murphy RJ; Menkes DB; Evans W; Hoeh N; Sundram F; Reynolds LM; Ponton R; Cavadino A; Smith T; Roop P; Allen N; Abeysinghe B; Svirskis D; Bansal M; Muthukumaraswamy S Trials; 2024 Aug; 25(1):560. PubMed ID: 39182140 [TBL] [Abstract][Full Text] [Related]
51. Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies. Fissler P; Vandersmissen A; Filippi M; Mavioglu RN; Scholkmann F; Karabatsiakis A; Krähenmann R J Psychopharmacol; 2023 Jul; 37(7):679-686. PubMed ID: 37122193 [TBL] [Abstract][Full Text] [Related]
52. What Can the Chemical Hold?: The Politics of Efficacy in the Psychedelic Renaissance. Hendy K Cult Med Psychiatry; 2022 Jun; 46(2):322-343. PubMed ID: 33650072 [TBL] [Abstract][Full Text] [Related]
53. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808 [TBL] [Abstract][Full Text] [Related]
54. Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. Prochazkova L; Lippelt DP; Colzato LS; Kuchar M; Sjoerds Z; Hommel B Psychopharmacology (Berl); 2018 Dec; 235(12):3401-3413. PubMed ID: 30357434 [TBL] [Abstract][Full Text] [Related]
55. Psychedelia: The interplay of music and psychedelics. Jerotic K; Vuust P; Kringelbach ML Ann N Y Acad Sci; 2024 Jan; 1531(1):12-28. PubMed ID: 37983198 [TBL] [Abstract][Full Text] [Related]